

Extended-spectrum beta-lactamases among *Klebsiella pneumoniae* from Iraqi patients with community-acquired pneumonia

Faez Erees Abdul Raouf¹ , Elhassan Benyagoub^{2,3} , Miaad K. Alkhudairy⁴ ,
Sousan Akrami^{5,6} , Morteza Saki^{5,6,7*} 

SUMMARY

OBJECTIVE: Beta-lactams resistance is a major clinical problem in treating pneumonia. This study aimed to detect the extended-spectrum beta-lactamases (ESBL) genes in *Klebsiella pneumoniae* among patients with community-acquired pneumonia (CAP) in Al-Najaf City, Iraq.

METHODS: A total of 511 sputum samples were obtained from all suspected patients with CAP in Al-Najaf City, Iraq, from March 2020 to September 2020. Sputum samples were subjected to microbiological tests. The disk diffusion method was used to test antibiotic sensitivity. Production of ESBLs was identified using phenotypic and genotypic methods.

RESULTS: The total prevalence of *K. pneumoniae* was 31.9% (163/511). Using CHROM agar, 41 (25.2%) isolates were ESBL producers. The imipenem 0.0% (n=0/41) and norfloxacin 0.0% (n=0/41) were the most effective antibiotics. The multiplex polymerase chain reaction showed that 46.3% (n=19/41) of isolates harbored ESBL genes. Out of 19 ESBL producers, 47.4% and 15.8% harbored *bla*_{CTX-M} and *bla*_{SHV}, respectively. While *bla*_{CTX-M} and *bla*_{SHV} genes were detected in 7 (36.8%) isolates, simultaneously.

CONCLUSIONS: The imipenem and norfloxacin can be used in empirical treatment of *K. pneumoniae* isolates in Iraq. The emergence of *K. pneumoniae* strains harboring ESBL resistance genes necessitates the development of a regular surveillance program to prevent the spreading of these isolates more in Iraqi health care systems.

KEYWORDS: *bla*_{CTX-M}; CAP; ESBL; Pneumonia; *Klebsiella pneumoniae*.

INTRODUCTION

According to the British Thoracic Society, community-acquired pneumonia (CAP) is an acute symptomatic infection of the lung parenchyma that occurs outside a hospital or nursing home¹. CAP is caused by various microorganisms including *Klebsiella pneumoniae*². No exact information about the incidence of the CAP in Iraq has been found so far. Clinical burden of CAP in older adults has only been assessed by a few large databases, with incidence rates ranging from 7.6 to 13.4 per 1,000 individuals³. A previous study from Iraq revealed *K. pneumoniae* as the leading cause of pneumonia⁴.

Strains of *K. pneumoniae* that can produce extended-spectrum beta-lactamases (ESBLs) become seriously active against

many types of beta-lactam antibiotics. In addition, these virulent strains are capable of becoming resistant to numerous classes of non-beta-lactams, making it difficult to treat infections, and are referred to as multidrug-resistant (MDR) strains⁵.

Nearly 450 forms of ESBLs enzymes have been documented worldwide, and among these types, *bla*_{SHV}, *bla*_{TEM}, and *bla*_{CTX-M} were predominant. ESBLs are enzymes that contribute to resistance to a variety of beta-lactams⁶. ESBLs hydrolyze the beta-lactam ring of beta-lactam antibiotics, causing these antibiotics to lose their antimicrobial activity. These factors may contribute to the development of pneumonia complications^{6,7}.

To date, there are no studies on the prevalence of ESBL-producing *K. pneumoniae* in patients with CAP in Iraq. Therefore,

¹Optometry Department, Al-Najaf Technical Institute, Al-Furat Al-Awsat Technical University, Kufa, Iraq.

²Department of Biology, Faculty of Life and Natural Sciences, Mohammed Tahri University of Béchar, (08000), Béchar, Algeria.

³Archipel Laboratory, Mohammed Tahri University of Béchar, (08000), Béchar, Algeria

⁴Department of Community Health Techniques, College of Health and Medical Techniques, Al-Furat Al-Awsat Technical University, Kufa, Iraq.

⁵Department of Microbiology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

⁶Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

⁷Infectious Ophthalmologic Research Center, Imam Khomeini Hospital Clinical Research Development Unit, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

*Corresponding author: mortezasaki1981@gmail.com

Conflicts of interest: the authors declare there is no conflicts of interest. Funding: none.

Received on February 16, 2022. Accepted on March 05, 2022.

the present research attempted to identify the ESBL-producing *K. pneumoniae* in Iraqi patients with CAP by phenotypic and molecular genotypic methods.

METHODS

Sample collection and bacterial isolation

The sputum samples of suspected patients suffering from CAP referred to Al-Sader Teaching Hospital in Al-Najaf City, Iraq, from March 2020 to September 2020 were collected in sterile containers. All patients were selected and diagnosed by a respiratory infectious disease specialist based on clinical examination and radiological and laboratory findings. Sputums were processed within 1 to 2 h of collection, using standard microbiological procedures. Sputums were initially cultured on blood agar and MacConkey agar (Merck, Germany) and incubated at 37°C for 2 days. The suspected *K. pneumoniae* colonies were further tested and identified using a panel of appropriate biochemical tests, including citrate utilization, urease, methyl red/Voges Proskauer, and triple sugar iron agar⁸. The confirmed *K. pneumoniae* isolates were stocked in tryptic soy broth containing 20% glycerol and placed at -80°C for long preservation.

Phenotypic detection of ESBL-producing *K. pneumoniae*

CHROM agar

All *K. pneumoniae* isolates were streaked on plates of CHROMagar™ ESBL agar (Pioneer, France). Chrome agar plates were aerobically incubated at 35°C overnight. Colonies of ESBL producers were appeared greenish blue.

Antimicrobial susceptibility testing

The ESBL-producing *K. pneumoniae* isolates were tested for antimicrobial susceptibility testing (AST) using disk diffusion technique according to the Clinical and Laboratory Standards Institute (CLSI) instructions⁹. Antimicrobials were classified as follows: aztreonam (ATM, 30 µg), gentamicin (CN, 10 µg), ciprofloxacin (CIP, 5 µg), ceftazidime (CAZ, 30 µg), levofloxacin (LEV, 5 µg), amoxicillin/clavulanate (AMC, 30 µg), trimethoprim (TMP, 5 µg), norfloxacin (NOR, 10 µg), cefotaxime (CTX, 30 µg), nitrofurantoin (F, 300 µg), imipenem (IPM, 10 µg), chloramphenicol (C, 30 µg), tetracycline (TE, 30 µg), and ceftriaxone (CRO, 30 µg) (Bioanalyse, Turkey). MDR isolates were determined according to the previous definition (resistance to at least one member of three antibiotics

classes)¹⁰. *Escherichia coli* ATCC 25922 and *K. pneumoniae* ATCC 700603 were used as quality control strains.

Molecular detection of ESBL genes among *K. pneumoniae*

The presence of ESBLs encoding genes (*bla*_{SHV} and *bla*_{CTX-M}) were investigated by multiplex polymerase chain reaction (M-PCR) using previously described primer pairs (Bioneer, Korea)¹¹. The DNA was extracted using genomic DNA extraction kit (FavorPrep, USA), according to the supplier instructions. All the components of M-PCR were mixed in final volume of 20 µl as follows: 12.5 µl of Master Mix (iNtRON, Korea), 5 µl of DNA template, 1.5 µl of DNA/RNA free water, and 0.5 µl of each reverse and forward primer. M-PCR mixture was put in a thermocycler (Biosystems, USA) instrument with following program: initial denaturation at 94°C for 5 min, 35 cycles of denaturation at 94°C for 50 s, annealing at 50°C for 40 s, elongation at 72°C for 60 s, and final extension at 72°C for 5 min. *E. coli* NCTC 13353 and *K. pneumoniae* ATCC 700603 were used as *bla*_{CTX-M}- and *bla*_{SHV}-positive controls, respectively.

Statistical analysis

The data for this research were analyzed statistically using the Statistical Package for Social Science (SPSS) version 20.0 (IBM Corp., Armonk, NY, USA).

RESULTS

Bacterial isolation

In total, 511 sputum samples were taken from 302 (59.1%) male and 209 (40.9%) female patients with CAP, from which 148 (29.0%) Gram-positive bacteria and 308 (60.3%) Gram-negative bacteria (GNB) were isolated. Also, 55 (10.7%) samples showed no bacterial growth. Out of 308 GNB, 163 (52.9%) isolates were identified as *K. pneumoniae* and were recorded as a major cause for pneumonia in this study. These isolates were obtained from 102 (62.6%) males and 61 (37.4%) females, respectively. The total prevalence of *K. pneumoniae* was 31.9% (163/511).

Phenotypic detection of ESBL producers

Using CHROM agar method, 41 (25.2%) and 122 (74.8%) *K. pneumoniae* isolates were found to be ESBL producers and non-ESBL producers, respectively.

Antibiotic susceptibility testing

This test was carried out on all ESBL-producing *K. pneumoniae* isolates against 14 antibiotics (Table 1). The ceftazidime

Table 1. An antimicrobial susceptibility testing of 41 extended-spectrum beta-lactamases producing isolates of *Klebsiella pneumoniae*.

Antibiotic agent	Number (%) of isolates		
	Resistance	Intermediate	Susceptible
Amoxicillin/clavulanate	18 (43.9)	0 (0.0)	23 (56.1)
Aztreonam	39 (95.1)	0 (0.0)	2 (4.9)
Cefotaxime	40 (97.6)	0 (0.0)	1 (2.4)
Ceftazidime	41 (100.0)	0 (0.0)	0 (0.0)
Ceftriaxone	38 (92.7)	0 (0.0)	3 (7.3)
Chloramphenicol	17 (41.5)	3 (7.3)	21 (51.2)
Ciprofloxacin	11 (26.8)	0 (0.0)	30 (73.2)
Gentamicin	19 (46.3)	3 (7.4)	19 (46.3)
Imipenem	0 (0.0)	0 (0.0)	41 (100.0)
Levofloxacin	9 (22.0)	2 (4.9)	30 (73.1)
Nitrofurantoin	9 (22.0)	0 (0.0)	32 (78.0)
Norfloxacin	0 (0.0)	0 (0.0)	41 (100.0)
Tetracycline	29 (70.7)	0 (0.0)	12 (29.3)
Trimethoprim	27 (65.9)	0 (0.0)	14 (34.1)

(n=41/41; 100%), cefotaxime (n=40/41; 97.6%), ceftriaxone (n=38/41; 92.7%), and aztreonam (n=39/41; 95.1%) were among the less effective antibiotics, while imipenem (n=0/41; 0.0%) and norfloxacin (n=0/41; 0.0%) were the most effective antimicrobials. In total, 27 (65.9%) ESBL-producing *K. pneumoniae* isolates were MDR due to the resistance to at least one member of three antibiotics classes.

Molecular detection of ESBLs encoding genes

The M-PCR showed that 46.3% (n=19/41) of isolates harbored ESBL genes, while 53.7% (n=22/41) of isolates were found to be negative for these genes. Out of total 19 ESBL-positive isolates, 47.4% (n=9) harbored *bla*_{CTX-M} and 15.8% (n=3) harbored *bla*_{SHV} genes. And, *bla*_{CTX-M} and *bla*_{SHV} genes were detected in 7 (36.8%) isolates simultaneously. The *bla*_{CTX-M} was the most dominant gene and present either alone or in combination with *bla*_{SHV} gene.

DISCUSSION

In this study, the bacterial isolates were obtained from 89.2% (n=456/511) of the CAP patients, which was significantly higher than those obtained in the studies by Kishimbo et al.¹ from Tanzania (20.4%) and Regassa¹² from South Ethiopia (42.9%). These discrepancies may be due to differences in the study population, sample size, and geographical variations. This study

showed more prevalence of CAP in male patients than females, which was consistent with previous report from Australia¹³.

In this study, the total prevalence of *K. pneumoniae* was 31.9% among patients with CAP. This finding was lower than the previous study (54.0%) by Jaaffar et al.⁴ from Iraq and higher (18.0%) than the former studies by Temesgen et al.¹⁴ from Ethiopia.

In this study, the ESBL-producing *K. pneumoniae* showed high resistance rates against ceftazidime (100.0%), cefotaxime (97.6%), aztreonam (95.1%), ceftriaxone (92.7%), tetracycline (70.7%), and trimethoprim (65.9%), whereas all isolates were susceptible to imipenem and norfloxacin. These results were closely similar to those observed by Fils et al.¹⁵ from France and Liu et al.¹⁶ from China. In this research, *K. pneumoniae* isolates showed good susceptibility to fluoroquinolones and aminoglycosides. In line with our results, Zhang et al.¹⁷ from China reported the good efficacy of ciprofloxacin and levofloxacin against *K. pneumoniae* causing community-onset infections.

Another finding of this study was the high frequency of 65.9% for MDR phenotype among ESBL-producing *K. pneumoniae* isolates. This finding was in parallel with the previous reports from Brazil (84.0%)¹⁰ and Portugal (100%)¹⁸. Teklu et al.¹⁹ concluded that the main explanation for these high resistance rates may be due to the widespread, excessive, irregular, unnecessary, and uncontrolled use of antibiotics to treat various infections. Carbapenems are still used as the best option to treat various infections, including pneumonia caused by ESBL-producing GNB. The results of this study were in agreement to the findings of most international studies, according to which imipenem has high efficacy against ESBL-producing *K. pneumoniae*²⁰⁻²².

In this study, 25.2% (n=41/163) of *K. pneumoniae* isolates showed phenotypic positive result for ESBL production using CHROM agar. Ultimately, this research was unable to validate the existence of ESBL genes by M-PCR in all isolates that had phenotypic positive test. It was found that 19 of 41 ESBL producers harbored ESBL genes using M-PCR method. These findings may presumably be due to the involvement of additional resistance pathways such as Ambler class C beta-lactamases, the presence of other mechanisms of resistance to beta-lactams, and the presence of other ESBL genes such as *bla*_{TEM} and *bla*_{PER} leading to differences between the results of phenotypic and molecular methods^{23,24}. According to the CLSI, the combination disk test (CDST) is recommended for confirmation of ESBL production in Enterobacteriaceae using CAZ (30 µg) and CTX (30 µg) alone and in combination with clavulanic acid⁹.

The results of this study showed that *bla*_{CTX-M} was the most common ESBL gene among *K. pneumoniae* isolates.

The worldwide spread of *bla*_{CTX-M} producing *K. pneumoniae* is a major concern in most continents. In a meta-analysis by Eskandari-Nasab et al.²⁵, the prevalence of *bla*_{CTX-M} was documented in Bahrain, Turkey, Saudi Arabia, Iran, United Arab Emirates, Pakistan, and Kuwait as 10.0, 30.0, 35.3, 56.7, 64.4, 96.9, and 100.0%, respectively. While international studies recorded varying percentages for the presence of this gene among the isolates producing ESBLs, including North Africa, America, Russia, Latin America, Brazil, and European countries, the percentages were 7.4, 26.4, 34.9, 61.1, 62.1, and 84.5%, respectively²⁵. Despite the fact that TEM and SHV variants are the most universal ESBLs, it seems that they have become less common over the past decade than CTX-M. The results of this study were consistent with previous studies that found the *bla*_{CTX-M} gene as the most widespread ESBL type in *K. pneumoniae* isolates^{16,17,25}. However, Ferreira et al.¹⁰ from Brazil and Carvalho et al.¹⁸ from Portugal showed a higher prevalence of *bla*_{SHV} compared to *bla*_{CTX-M} in *K. pneumoniae*, which was in contrast to our finding. Many factors, including the sample origin, sample size, studied population, and detection methods, can contribute to these differences.

Finally, our results showed the co-existence of ESBL genes in 36.8% of *K. pneumoniae* isolates. Previous studies from

Brazil¹⁰, China^{16,17}, and Portugal¹⁸ reported the co-existence of various ESBL genes among clinical isolates of *K. pneumoniae*. This study had several limitations: the lack of screening of other ESBL genes such as *bla*_{TEM} and *bla*_{PER}, the lack of clinical data of patients to investigate the ESBL-related risk factors, and lack of sequencing for detected ESBL genes.

CONCLUSIONS

The emergence of MDR *K. pneumoniae* strains harboring ESBL resistance genes necessitates the development of a regular surveillance program to monitor, control, and prevent the more spread of these isolates in Iraqi health care systems.

AUTHORS' CONTRIBUTIONS

FEAR: Conceptualization, Data curation, Formal analysis, Writing – original draft, Writing – review & editing. **EB:** Conceptualization, Data curation, Formal analysis, Writing – original draft, Writing – review & editing. **MKA:** Conceptualization, Data curation, Formal analysis, Writing – original draft, Writing – review & editing. **SA:** Conceptualization, Formal analysis, Writing – original draft, Writing – review & editing. **MS:** Formal analysis, Writing – original draft.

REFERENCES

1. Kishimbo P, Sogone NM, Kalokola F, Mshana SE. Prevalence of gram negative bacteria causing community acquired pneumonia among adults in Mwanza City, Tanzania. *Pneumonia* (Nathan). 2020;12:7. <https://doi.org/10.1186/s41479-020-00069-0>
2. Chen J, Li X, Wang W, Jia Y, Lin F, Xu J. The prevalence of respiratory pathogens in adults with community-acquired pneumonia in an outpatient cohort. *Infect Drug Resist*. 2019;12:2335-41. <https://doi.org/10.2147/IDR.S213296>
3. Lopardo GD, Fridman D, Raimondo E, Albornoz H, Lopardo A, Bagnulo H, et al. Incidence rate of community-acquired pneumonia in adults: a population-based prospective active surveillance study in three cities in South America. *BMJ Open*. 2018;8(4):e019439. <https://doi.org/10.1136/bmjopen-2017-019439>
4. Jaaffar AI, Al-Mahmood S, Maeh RK, Alyasiry M. Microbiological profile with antibiotic resistance pattern in patients of pneumonia in Iraq. *Drug Invention Today*. 2019;11(11):2913-16.
5. Silva Y, Ferrari R, Marin VA, Conte Junior CA. A global overview of β -lactam resistance genes in *Klebsiella pneumoniae*. *Open Infect Dis J*. 2019;11:22-34. <https://doi.org/10.2174/1874279301911010022>
6. Al-Garni SM, Ghonaim MM, Ahmed MMM, Al-Ghamdi AS, Ganai FA. Risk factors and molecular features of extended-spectrum beta-lactamase producing bacteria at southwest of Saudi Arabia. *Saudi Med J*. 2018;39(12):1186-94. <http://doi.org/10.15537/smj.2018.12.23273>
7. Rahman SU, Ali T, Ali I, Khan NA, Han B, Gao J. The growing genetic and functional diversity of extended spectrum beta-lactamases. *Biomed Res Int*. 2018;2018:9519718. <http://doi.org/10.1155/2018/9519718>
8. Collee JG, Miles RS, Watt B. Tests for the identification of bacteria. In: Collee JG, Fraser AG, Marmion BP, Simmons A, eds. *Mackie and McCartney practical microbiology*. 14th ed. New York: Churchill Livingstone; 1996. p. 131-51.
9. Weinstein MP, Patel JB, Campeau S, Eliopoulos GM, Galas MF, Humphries RM, et al. M100. Performance standards for antimicrobial susceptibility testing. 28th ed. Wayne Clinical and Laboratory Standards Institute; 2018. Available from: <https://file.qums.ac.ir/repository/mmrc/CLSI-2018-M100-S28.pdf>
10. Ferreira RL, Silva BCM, Rezende GS, Nakamura-Silva R, Pitondo-Silva A, Campanini EB, et al. High prevalence of multidrug-resistant *Klebsiella pneumoniae* harboring several virulence and β -lactamase encoding genes in a Brazilian intensive care unit. *Front Microbiol*. 2019;9:3198. <http://doi.org/10.3389/fmicb.2018.03198>
11. Bello-López JM, Rojo-Medina J. Detection of antibiotic resistance genes β -lactams in bacterial strains isolated from Umbilical Cord Blood Units for transplant. *Rev Med Hosp Gen Méx*. 2017;80(1):31-6. <https://doi.org/10.1016/j.hgmx.2016.05.005>
12. Regassa B. Drug resistance patterns of bacterial pathogens from adult patients with pneumonia in Arba Minch Hospital, South Ethiopia. *J Med Microb Diagn*. 2014;3(4):1000151. <https://doi.org/10.4172/2161-0703.1000151>
13. Tsai D, Chiong F, Secombe P, Hnin KM, Stewart P, Goud R, et al. Epidemiology and microbiology of severe community-acquired pneumonia in Central Australia: a retrospective study. *Int Med J*. 2020. <https://doi.org/10.1111/imj.15171>

14. Temesgen D, Bereded F, Derbie A, Biadlegne F. Bacteriology of community acquired pneumonia in adult patients at Felege Hiwot Referral Hospital, Northwest Ethiopia: a cross-sectional study. *Antimicrob Resist Infect Control*. 2019;8:101. <https://doi.org/10.1186/s13756-019-0560-0>
15. Fils PEL, Cholley P, Gbaguidi-Haore H, Hocquet D, Sauget M, Bertrand X. ESBL-producing *Klebsiella pneumoniae* in a University hospital: molecular features, diffusion of epidemic clones and evaluation of cross-transmission. *PLoS One*. 2021;16(3):e0247875. <https://doi.org/10.1371/journal.pone.0247875>
16. Liu J, Du SX, Zhang JN, Liu SH, Zhou YY, Wang XR. Spreading of extended-spectrum β -lactamase-producing *Escherichia coli* ST131 and *Klebsiella pneumoniae* ST11 in patients with pneumonia: a molecular epidemiological study. *Chin Med J (Engl)*. 2019;132(16):1894-902. <https://doi.org/10.1097/CM9.0000000000000368>
17. Zhang J, Zhou K, Zheng B, Zhao L, Shen P, Ji J, et al. High prevalence of ESBL-producing *Klebsiella pneumoniae* causing community-onset infections in China. *Front Microbiol*. 2016;7:1830. <https://doi.org/10.3389/fmicb.2016.01830>
18. Carvalho I, Carvalho JA, Martínez-Álvarez S, Sadi M, Capita R, Alonso-Calleja C, et al. Characterization of ESBL-producing *Escherichia coli* and *Klebsiella pneumoniae* isolated from clinical samples in a Northern Portuguese Hospital: predominance of CTX-M-15 and high genetic diversity. *Microorganisms*. 2021;9(9):1914. <https://doi.org/10.3390/microorganisms9091914>
19. Teklu DS, Negeri AA, Legese MH, Bedada TL, Woldemariam HK, Tullu KD. Extended-spectrum beta-lactamase production and multi-drug resistance among *Enterobacteriaceae* isolated in Addis Ababa, Ethiopia. *Antimicrob Resist Infect Control*. 2019;8:39. <https://doi.org/10.1186/s13756-019-0488-4>
20. Gutiérrez-Gutiérrez B, Rodríguez-Baño J. Current options for the treatment of infections due to extended-spectrum beta-lactamase-producing *Enterobacteriaceae* in different groups of patients. *Clin Microbiol Infect*. 2019;25(8):932-42. <https://doi.org/10.1016/j.cmi.2019.03.030>
21. Yazdanesad S, Alkhudhairy MK, Najafpour R, Farajtabrizi E, Al-Mosawi RM, Saki M, et al. Preliminary survey of extended-spectrum β -lactamases (ESBLs) in nosocomial uropathogen *Klebsiella pneumoniae* in north-central Iran. *Heliyon*. 2019;5(9):e02349. <https://doi.org/10.1016/j.heliyon.2019.e02349>
22. Benyagoub E, Alkhudhairy MK, Benchaib SM, Zaalán A, Mekhfi Y, Teyebi N, et al. Isolation frequency of uropathogenic strains and search for ESBL producing *Enterobacteriaceae* isolated from patients with UTI in Bechar (Algeria). *Anti-Infective Agents*. 2021;19(3):303-16. <http://doi.org/10.2174/2211352518999201224102209>
23. Alkhudhairy MK, Alshammari MMM. Extended spectrum β -lactamase-producing *Escherichia coli* isolated from pregnant women with asymptomatic UTI in Iraq. *Eurasia J Biosci*. 2019;13:1881-89.
24. Correa-Martínez CL, Idelevich EA, Spärbier K, Kostrzewa M, Becker K. Rapid detection of extended-spectrum β -lactamases (ESBL) and AmpC β -lactamases in *Enterobacterales*: development of a screening panel using the MALDI-TOF MS-based direct-on-target microdroplet growth assay. *Front Microbiol*. 2019;10:13. <http://doi.org/10.3389/fmicb.2019.00013>
25. Eskandari-Nasab E, Moghadampour M, Tahmasebi A. Prevalence of *bla*_{CTX-M} gene among extended-spectrum β -lactamases producing *Klebsiella pneumoniae* clinical isolates in Iran: a meta-analysis. *Iran J Med Sci*. 2018;43(4):347-54. PMID: 30046202

